journal
MENU ▼
Read by QxMD icon Read
search

Journal of Ocular Pharmacology and Therapeutics

journal
https://www.readbyqxmd.com/read/28426277/topical-ganciclovir-in-cytomegalovirus-anterior-uveitis
#1
Joelle Antoun, François Willermain, Dorine Makhoul, Elie Motulsky, Laure Caspers, Lia Judice Relvas
PURPOSE: To study the effects of topical ganciclovir 0.15% gel on cytomegalovirus (CMV) anterior uveitis in a tertiary uveitis referral center in Brussels, Belgium. METHODS: A retrospective study of patients with a clinical diagnosis of CMV anterior uveitis/endotheliitis demonstrated by a positive polymerase chain reaction and/or Goldmann-Witmer coefficient (GWc). RESULTS: We report a series of 15 patients presenting clinical characteristics of CMV anterior uveitis...
April 20, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28422545/response-to-aslankurt-et-al-re-safety-profile-of-stromal-hydration-of-clear-corneal-incisions-with-cefuroxime-in-the-mouse-model
#2
Mariya Moosajee, Veronica Ferguson
No abstract text is available yet for this article.
April 19, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28414592/understanding-the-presence-and-roles-of-ap4a-diadenosine-tetraphosphate-in-the-eye
#3
Almudena Crooke, Ana Guzman-Aranguez, Gonzalo Carracedo, Maria J Perez de Lara, Jesus Pintor
Diadenosine tetraphosphate abbreviated Ap4A is a naturally occurring dinucleotide, which is present in most of the ocular fluids. Due to its intrinsic resistance to enzyme degradation compared to mononucleotides, this molecule can exhibit profound actions on ocular tissues, including the ocular surface, ciliary body, trabecular meshwork, and probably the retina. The actions of Ap4A are mostly carried out by P2Y2 receptors, but the participation of P2X2 and P2Y6 in processes such as the regulation of intraocular pressure (IOP), together with the P2Y2, is pivotal...
April 17, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28414561/interferon-alpha-for-the-treatment-of-cystoid-macular-edema-associated-with-presumed-ocular-tuberculosis
#4
Merih Oray, Sumru Onal, Gunay Uludag, Aylin Koc Akbay, Ilknur Tugal-Tutkun
PURPOSE: To report the efficacy and safety of interferon (IFN) α-2a in patients with cystoid macular edema (CME) associated with presumed ocular tuberculosis (TB). METHODS: We reviewed the clinical records of 5 patients with presumed ocular TB who had been treated with IFN α-2a for recurrent CME during or after completion of anti-tubercular therapy. IFN α-2a was administered at an initial dose of 3 million IU per day and then tapered after the initial response...
April 17, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28402720/insulin-like-growth-factor-binding-protein-related-protein-1-inhibit-retinal-neovascularization-in-the-mouse-model-of-oxygen-induced-retinopathy
#5
Ping Zhang, Hong Wang, Hui Cao, Xun Xu, Tao Sun
PURPOSE: To explore the inhibitory effect of insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) on retinal angiogenesis and its underlying molecular mechanisms in the mouse model of oxygen-induced retinopathy (OIR). METHODS: C57BL/6J mice were classified into three groups as control group, OIR nonintervention group, and OIR intervention group. Postnatal day 12 (P12) mice in OIR intervention group were received recombinant mouse IGFBP-rP1 (50, 100, and 200 ng/mL) intravitreal injection...
April 12, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28394239/management-of-uveitis-and-scleritis-in-necrobiotic-xanthogranuloma
#6
John A Gonzales, Anna Haemel, Andrew J Gross, Nisha R Acharya
Necrobiotic xanthogranuloma (NXG) is a chronic, progressive non-Langerhans histiocytic granulomatous disease. While case reports describing periorbital involvement of NXG are frequent, only a few case reports describing ocular involvement, such as scleritis and uveitis, exist. Herein, we present a case presenting initially as bilateral anterior and posterior scleritis, as well as a chronic bilateral granulomatous panuveitis, and discuss the immunosuppressant options that should be considered for this disease with protean manifestations...
April 10, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28384009/incidence-and-timing-of-the-first-recurrence-in-neovascular-age-related-macular-degeneration-comparison-between-ranibizumab-and-aflibercept
#7
Jae Hui Kim, Young Suk Chang, Dong Won Lee, Chul Gu Kim, Jong Woo Kim
PURPOSE: To compare the incidence and timing of first recurrence between patients who were treated with ranibizumab and aflibercept in neovascular age-related macular degeneration (AMD). METHODS: This retrospective study included 120 patients who received the diagnosis of treatment-naive typical neovascular AMD or polypoidal choroidal vasculopathy (PCV) and were treated using either ranibizumab (n = 73) or aflibercept (n = 47). Recurrence within 10 months of the third injection was compared between the 2 treatment groups...
April 6, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375792/safety-and-efficacy-of-cortisol-phosphate-in-hyaluronic-acid-vehicle-in-the-treatment-of-dry-eye-in-sjogren-syndrome
#8
Maurizio Rolando, Aldo Vagge
PURPOSE: Evaluation of 0.3% cortisol phosphate eye drops in hyaluronic acid vehicle in the treatment of dry eye in Sjogren Syndrome. METHODS: This prospective, single-center, masked (single blind), randomized controlled study included 40 female patients divided into 2 groups, group 1 treated with Idracemi, 0.3% cortisol phosphate eye drops twice a day, and group 2 treated with Cortivis, 0.3% cortisol phosphate in hyaluronic acid vehicle, with the same posology. Screening (day -7), randomization (day 0), follow-up (day 7), and termination (day 28) visits were conducted...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375791/intravitreal-dexamethasone-implant-for-treatment-of-serous-macular-detachment-in-central-retinal-vein-occlusion
#9
Ahmet Elbay, Hakan Ozdemir, Arif Koytak, Arif Melikov
PURPOSE: To evaluate the effect of intravitreal dexamethasone implant (Ozurdex) treatment on serous macular detachment (SMD) in patients with nonischemic central retinal vein occlusion (CRVO). METHODS: Retrospective, interventional, noncomparative case series was conducted. Twenty-four eyes of 24 patients with macular edema (ME) and SMD secondary to nonischemic CRVO made up the study population. Patients who had received intravitreal triamcinolone and/or antivascular endothelial growth factor treatment and/or had undergone retinal photocoagulation were excluded from the study...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375790/the-effect-of-immunologically-safe-plasma-rich-in-growth-factor-eye-drops-in-patients-with-sj%C3%A3-gren-syndrome
#10
Ronald Mauricio Sanchez-Avila, Jesus Merayo-Lloves, Ana Cristina Riestra, Eduardo Anitua, Francisco Muruzabal, Gorka Orive, Luis Fernández-Vega
PURPOSE: The objective was to provide preliminary information about the efficacy and safety of immunologically safe plasma rich in growth factor (immunosafe PRGF) eye drops in the treatment of moderate to severe dry eye in patients with primary and secondary Sjögren's syndrome (SS) and to analyze the influence of several variables on treatment outcomes. METHODS: This retrospective study included patients with SS. All patients were treated with previously immunosafe PRGF eye drops to reduce the immunologic component contents...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375789/the-effect-of-tear-supplementation-with-0-15-preservative-free-zinc-hyaluronate-on-ocular-surface-sensations-in-patients-with-dry-eye
#11
Kristóf Perényi, Lóránt Dienes, Anna Kornafeld, Balázs Kovács, Huba J Kiss, Zsuzsanna Szepessy, Zoltán Z Nagy, Árpád Barsi, M Carmen Acosta, Juana Gallar, Illés Kovács
PURPOSE: To evaluate the effect of tear supplementation with preservative free 0.15% zinc-hyaluronate on ocular surface sensations and corneal sensitivity in dry eye patients. METHODS: Ocular surface sensations were assessed using the ocular surface disease index (OSDI) questionnaire and by recording ocular sensations during forced blinking in parallel with noninvasive tear film breakup time measurement in 20 eyes of 20 dry eye patients. Corneal sensitivity thresholds to selective stimulation of corneal mechano-, thermal- and chemical receptors were measured using the Belmonte gas esthesiometer...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28375788/real-world-experience-with-half-time-versus-half-dose-photodynamic-therapy-in-chronic-central-serous-chorioretinopathy
#12
Shu-Yen Peng, Chi-Chun Lai, Nan-Kai Wang, Wei-Chi Wu, Yih-Shiou Hwang, Kuan-Jen Chen, Lee-Jen Chen, Shawn Tsai, Wei-Chun Chan, Laura Liu, Ling Yeung
PURPOSE: To evaluate the real-world experience with half-time photodynamic therapy (PDT) versus half-dose PDT for chronic central serous chorioretinopathy (CSC). METHODS: This multicenter retrospective study enrolled patients who received half-time PDT (with irradiation time shortened to 42 s) or half-dose PDT (with the dosage of verteporfin reduced to 3 mg/m(2)) for chronic CSC and who were followed up for ≧12 months. The success rate, central subfield retinal thickness (CST), and best-corrected visual acuity (BCVA) were documented in each group of patients...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28355124/ocular-pharmacology-for-scleritis-review-of-treatment-and-a-practical-perspective
#13
Maxwell S Stem, Bozho Todorich, Lisa J Faia
Scleritis is defined as an infectious or noninfectious inflammation of the sclera that can be broadly categorized according to anatomic location (ie, anterior or posterior) and whether the process is necrotizing or non-necrotizing. Treatment for scleritis is dictated by the etiology of the inflammation, with infectious forms requiring treatment of the inciting agent and noninfectious forms requiring treatment of the underlying inflammation with immunosuppression. Pharmacotherapy for noninfectious scleritis can be classified according to delivery route (eg, local or systemic) and mechanism of action (eg, biologic or nonbiologic)...
March 29, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28355091/cytomegalovirus-retinitis-a-review
#14
Alexander D Port, Anton Orlin, Szilard Kiss, Sarju Patel, Donald J D'Amico, Mrinali P Gupta
Cytomegalovirus (CMV) is a ubiquitous DNA herpes virus that causes significant morbidity and mortality in immunocompromised individuals. CMV retinitis is a potentially blinding manifestation of CMV infection that was commonly seen in advanced acquired immunodeficiency syndrome (AIDS) in the era before modern combination antiretroviral therapy era, but is also recognized in patients with immune deficiency from multiple causes. The advent of and advances in antiretroviral therapies for human immunodeficiency virus have decreased the incidence of CMV retinitis by over 90% among AIDS patients, and improved visual outcomes in those affected...
March 29, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28346860/comparison-of-short-term-effects-of-diquafosol-and-rebamipide-on-mucin-5ac-level-on-the-rabbit-ocular-surface
#15
Yuichi Hori, Tomofumi Kageyama, Asuka Sakamoto, Tomoaki Shiba, Masatsugu Nakamura, Takatoshi Maeno
PURPOSE: To investigate the short-term effects of 2 new secretagogue eye drops for dry eye, 3% diquafosol tetrasodium ophthalmic solution (diquafosol) and 2% rebamipide ophthalmic suspension (rebamipide), on the concentration of mucin 5AC (MUC5AC) in rabbit tear fluid and conjunctival goblet cells. METHODS: One dose of artificial tears, diquafosol or rebamipide, was instilled into 8 eyes of Japanese white rabbits. MUC5AC concentration in the tear fluid was examined using the enzyme-linked immunosorbent assay 15 min after instillation and compared with 8 untreated controls...
March 27, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28338404/effect-of-histone-deacetylase-inhibitor-butyroyloxymethyl-diethyl-phosphate-an-7-on-corneal-neovascularization-in-a-mouse-model
#16
Michal Schaap-Fogler, Irit Bahar, Ada Rephaeli, Mor Dahbash, Abraham Nudelman, Eitan Livny, Tilda Barliya, Yael Nisgav, Tami Livnat
PURPOSE: To examine whether butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, inhibits chemically induced corneal neovascularization (NV) in mice. METHODS: Corneal NV was induced in the right eye of male C57BL mice by application of a mixture of 75% silver nitrate and 25% potassium nitrate to the corneal center. Immediately thereafter, the mice were randomized into 2 groups, receiving an intraperitoneal injection of AN-7 or saline, which served as control...
March 24, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28333572/new-insights-on-complement-inhibitor-cd59-in-mouse-laser-induced-choroidal-neovascularization-mislocalization-after-injury-and-targeted-delivery-for-protein-replacement
#17
Gloriane Schnabolk, Mee Keong Beon, Stephen Tomlinson, Bärbel Rohrer
PURPOSE: The membrane attack complex (MAC) in choriocapillaris (CC) and retinal pigment epithelium (RPE) increase with age and disease (age-related macular degeneration). MAC assembly can be inhibited by CD59, a membrane-bound regulator. Here we further investigated the role of CD59 in murine choroidal neovascularization (CNV), a model involving both CC and RPE, and tested whether CR2-CD59, a soluble targeted form of CD59, provides protection. METHODS: Laser-induced CNV was generated in wild type and CD59a-deficient mice (CD59(-/-))...
March 23, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28326865/eyes-on-new-product-development
#18
Gary D Novack
No abstract text is available yet for this article.
March 22, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28300477/evaluation-of-intracameral-pentablock-copolymer-thermosensitive-gel-for-sustained-drug-delivery-to-the-anterior-chamber-of-the-eye
#19
Elizabeth Schaefer, Sara M Smith, Jacklyn Salmon, Santhi Abbaraju, Rasidul Amin, Sidney Weiss, Ulrich Grau, Poonam Velagaleti, Brian Gilger
PURPOSE: To investigate PTSgels (Pentablock copolymers) as an injectable formulation technology for sustained ocular drug delivery. Drug release profile, tolerability, and polymer degradation for one of the thermosensitive, biodegradable, and biocompatible compositions were investigated through intracameral (IC) injection in rabbits. METHODS: New Zealand White rabbit eyes were injected IC (50 μL) with 100 μg near-infrared-immunoglobulin G (NIR-IgG) in balanced salt solution (BSS) or 20% PTSgel; or with PTSgel or BSS alone...
March 16, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28287852/cyclosporine-a-historical-perspective-on-its-role-in-the-treatment-of-noninfectious-uveitis
#20
Wendy M Smith
The history of cyclosporine and uveitis is intertwined with the development of experimental autoimmune uveitis (EAU) animal models and the understanding that T lymphocytes play a major role in the pathogenesis of uveitis. The early studies of CsA in uveitis also demonstrated the power of collaborative efforts in translational research. Dr. Robert Nussenblatt and his colleagues were the first to show that CsA can inhibit EAU. Over many years after the initial CsA experiments, Dr. Nussenblatt's group as well as others continued to study CsA under experimental conditions as well as in clinical trials with human patients...
March 13, 2017: Journal of Ocular Pharmacology and Therapeutics
journal
journal
32321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"